JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McCarthy, T. J.
Right arrow Articles by Welch, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCarthy, T. J.
Right arrow Articles by Welch, M. J.

Vol. 301, Issue 3, 878-883, June 2002

Positron Emission Tomography Shows that Intrathecal Leptin Reaches the Hypothalamus in Baboons

T. J. McCarthy, W. A. Banks, C. L. Farrell, S. Adamu, C. P. Derdeyn, A. Z. Snyder, R. Laforest, D. C. Litzinger, D. Martin, C. P. LeBel and M. J. Welch

Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri (T.J.M., C.P.D., A.Z.S., R.L., M.J.W.); Geriatric Research, Education and Clinical Center, Veterans Affairs Medical Center-St. Louis, and Saint Louis University School of Medicine, Division of Geriatrics, Department of Internal Medicine, St. Louis, Missouri (W.A.B.); Amgen, Inc., Thousand Oaks, California (C.L.F., S.A., D.M., C.P.L); and Eli Lilly and Company, Indianapolis, Indiana (D.C.L.)

Human obesity may be caused by a resistance to circulating leptin. Evidence from rodents and humans suggests that a major component of this resistance is an impairment in the ability of the blood-brain barrier (BBB) to transport leptin from the blood to the brain. One potential way to bypass the BBB is by administering leptin into the intrathecal (i.t.) space. To be effective, i.t. leptin would have to move caudally from the site of injection, enter the cranium, and reach the hypothalamic arcuate nucleus at the base of the pituitary fossa. However, many substances, especially small, lipid-soluble molecules, do not diffuse far from the site of i.t. injection but are resorbed back into blood. To determine whether i.t. leptin can move caudally, we injected leptin conjugated to diethylenetriaminepentaacetic acid (DTPA) and labeled with 68Ga (G-Ob) into the lumbar space of three baboons. We also studied unconjugated DTPA labeled with 68Ga, which did not move up the spinal cord but rapidly appeared in blood after i.t. injection. In contrast, G-Ob steadily moved toward the cranium and had reached the hypothalamus 91 and 139 min after i.t. injection in two baboons. We estimated the concentration of leptin in the hypothalamic region to be at least 8 ng/ml, which is about 40 times higher than cerebrospinal fluid levels in normal weight humans and about 4 times higher than the highest level ever recorded after the peripheral administration of leptin. In a third baboon, the leptin neither moved caudally nor appeared in the blood. We conclude that leptin administered i.t. can reach the hypothalamus in therapeutic concentrations, although there is considerable individual variation.


0022-3565/02/3013-0878$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by U.S. Government



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
W. A. Banks, M. J. During, and M. L. Niehoff
Brain Uptake of the Glucagon-Like Peptide-1 Antagonist Exendin(9-39) after Intranasal Administration
J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 469 - 475.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.